GSD Goldshield Grp

RNS No 0329d
GOLDSHIELD GROUP PLC
22 April 1999

                      Goldshield Group
                  Acquisition of Kamillosan
                              
Goldshield Group has today acquired Kamillosan from Norgine
Limited for #0.93m.

Kamillosan is currently market leader in the UK for the
treatment and prevention of sore nipples during breast
feeding. It is widely distributed throughout UK retail
outlets.

Breast feeding rates are currently rising within the UK as a
direct result of the breast feeding initiative within
maternity units.

Kamillosan has a rapid effect in relieving soreness and
chafing, which is a major reason for stopping breast feeding
prematurely.

Net sales of #350,000 are expected in the first full year of
trading. The majority of that will be generated in the UK
although product licenses have also been granted in a number
of overseas territories.

Ajit Patel, Chairman and Chief Executive of Goldshield Group
said..."Kamillosan is an ideal fit within the Goldshield OTC
portfolio which will sit comfortably alongside our existing
Infaderm range of products. It provides opportunities to
grow this sector of the business by adding a brand which is
widely known and respected."

Contact:

Goldshield Group plc                        0181 649 8500
Ajit Patel, Chairman & Chief Executive

Buchanan Communications                     0171 466 5000
Andy Yeo/Tom Gadsby


END


ACQNFPLFAFENEFN

Goldshield (LSE:GSD)
Historical Stock Chart
From Jun 2024 to Jul 2024

Goldshield (LSE:GSD)
Historical Stock Chart
From Jul 2023 to Jul 2024